Picture of Coherus Oncology logo

CHRS — Coherus Oncology News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Coherus BioSciences Inc reports results for the quarter ended in January - Earnings Summary

* Coherus BioSciences Inc  CHRS.OQ  reported a quarterly
adjusted
loss of 14 cents​​ per share for the quarter ended in January,
higher than the same quarter last year, when the company
reported EPS of -38 cents.  The mean expectation of
eight analysts for the quarter was for a loss of 29 cents per
share. Wall Street expected results to range from -38 cents
to -23 cents per share.
    * Revenue rose 10.7% to $64.98 million from a year ago;
analysts
expected $61.37 million. 
    * Coherus BioSciences Inc's reported EPS for the quarter was
a
loss of 11 cents​.
    * The company reported a quarterly loss of $12.92 million.
    * Coherus BioSciences Inc shares had fallen by 28.3% this
quarter and lost 62.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 29.5%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Coherus
BioSciences Inc is $8.00 
This summary was machine generated from LSEG data August 8 at
10:35 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.29          -0.14          Beat
 Mar. 31 2024      -0.24          -0.32          Missed
 Dec. 31 2023      -0.12          -0.62          Missed
 Sep. 30 2023      -0.27          -0.27          Met

Recent news on Coherus Oncology

See all news